Cargando…
Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS – Neurofilament as a Surrogate of Disease Progression
OBJECTIVE: Lamotrigine trial in SPMS was a randomised control trial to assess whether partial blockade of sodium channels has a neuroprotective effect. The current study was an additional study to investigate the value of neurofilament (NfH) and other biomarkers in predicting prognosis and/or respon...
Autores principales: | Gnanapavan, Sharmilee, Grant, Donna, Morant, Steve, Furby, Julian, Hayton, Tom, Teunissen, Charlotte E., Leoni, Valerio, Marta, Monica, Brenner, Robert, Palace, Jacqueline, Miller, David H., Kapoor, Raj, Giovannoni, Gavin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3731296/ https://www.ncbi.nlm.nih.gov/pubmed/23936370 http://dx.doi.org/10.1371/journal.pone.0070019 |
Ejemplares similares
-
CSF neurofilament light chain testing as an aid to determine treatment strategies in MS
por: Reyes, Saúl, et al.
Publicado: (2020) -
The Evolution of Neurofilament Light Chain in Multiple Sclerosis
por: Ferreira-Atuesta, Carolina, et al.
Publicado: (2021) -
The relationship of cerebrospinal fluid neurofilament levels with magnetic resonance imaging lesion location and disease activity in multiple sclerosis
por: Adams, Ashok, et al.
Publicado: (2022) -
Progression in multiple sclerosis is associated with low endogenous NCAM
por: Gnanapavan, Sharmilee, et al.
Publicado: (2013) -
Development of protein biomarkers in cerebrospinal fluid for secondary progressive multiple sclerosis using selected reaction monitoring mass spectrometry (SRM-MS)
por: Jia, Yan, et al.
Publicado: (2012)